Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Predictors of Local Control of Brain Metastasis Treated With Laser Interstitial Thermal Therapy.

Bastos DCA, Rao G, Oliva ICG, Loree JM, Fuentes DT, Stafford RJ, Beechar VB, Weinberg JS, Shah K, Kumar VA, Prabhu SS.

Neurosurgery. 2019 Sep 20. pii: nyz357. doi: 10.1093/neuros/nyz357. [Epub ahead of print]

PMID:
31539421
2.

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.

Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K.

JAMA Oncol. 2019 Aug 15:e191870. doi: 10.1001/jamaoncol.2019.1870. [Epub ahead of print]

PMID:
31415071
3.

Mechanisms of Innate and Acquired Resistance to Anti-EGFR therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies.

Parseghian CM, Napolitano S, Loree JM, Kopetz S.

Clin Cancer Res. 2019 Jul 1. doi: 10.1158/1078-0432.CCR-19-0823. [Epub ahead of print] Review.

PMID:
31263029
4.

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.

Williamson LM, Steel M, Grewal JK, Thibodeau ML, Zhao EY, Loree JM, Yang KC, Gorski SM, Mungall AJ, Mungall KL, Moore RA, Marra MA, Laskin J, Renouf DJ, Schaeffer DF, Jones SJM.

Cold Spring Harb Mol Case Stud. 2019 Jun 3;5(3). pii: a003814. doi: 10.1101/mcs.a003814. Print 2019 Jun.

5.

Clinical and molecular characterization of early-onset colorectal cancer.

Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM.

Cancer. 2019 Jun 15;125(12):2002-2010. doi: 10.1002/cncr.31994. Epub 2019 Mar 11.

PMID:
30854646
6.

Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer.

Tsang ES, Wong HL, Wang Y, Renouf DJ, Cheung WY, Lim HJ, Gill S, Loree JM, Kennecke HF.

Am J Clin Oncol. 2019 Feb;42(2):196-201. doi: 10.1097/COC.0000000000000500.

PMID:
30499841
7.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S.

Ann Oncol. 2019 Feb 1;30(2):243-249. doi: 10.1093/annonc/mdy509.

PMID:
30462160
8.

Clinical application of cfDNA: moving in the right direction, but still a long way to go.

Mendis S, Loree JM.

Oncotarget. 2018 Oct 16;9(81):35199-35200. doi: 10.18632/oncotarget.26224. eCollection 2018 Oct 16. No abstract available.

9.

Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.

Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S.

Clin Colorectal Cancer. 2018 Dec;17(4):e699-e709. doi: 10.1016/j.clcc.2018.07.005. Epub 2018 Jul 17.

10.

Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

Kim CA, Ahmed S, Ahmed S, Brunet B, Chalchal H, Deobald R, Doll C, Dupre MP, Gordon V, Lee-Ying RM, Lim H, Liu D, Loree JM, McGhie JP, Mulder K, Park J, Yip B, Wong RP, Zaidi A; Western Canadian Gastrointestinal Cancer Group.

Curr Oncol. 2018 Aug;25(4):275-284. doi: 10.3747/co.25.4109. Epub 2018 Aug 14.

11.

Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis.

Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, Loree JM, Mehrvarz Sarshekeh A, Bressler J, Lopez DS, Daniel CR, Swartz MD, Kopetz S.

Transl Oncol. 2018 Oct;11(5):1188-1201. doi: 10.1016/j.tranon.2018.07.008. Epub 2018 Jul 30.

12.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
13.

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.

Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K.

J Natl Cancer Inst. 2018 Dec 1;110(12):1409-1417. doi: 10.1093/jnci/djy067.

14.

Correction to: Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S.

Curr Treat Options Oncol. 2018 Apr 23;19(5):25. doi: 10.1007/s11864-018-0537-x.

PMID:
29687230
15.

Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S.

Curr Treat Options Oncol. 2018 Feb 27;19(2):11. doi: 10.1007/s11864-018-0524-2. Review. Erratum in: Curr Treat Options Oncol. 2018 Apr 23;19(5):25.

PMID:
29488033
16.

Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.

Loree JM, Sha A, Soleimani M, Kennecke HF, Ho MY, Cheung WY, Mulder KE, Abadi S, Spratlin JL, Gill S.

Clin Colorectal Cancer. 2018 Jun;17(2):156-163. doi: 10.1016/j.clcc.2018.01.010. Epub 2018 Feb 7.

PMID:
29486916
17.

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.

Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009. Epub 2017 Dec 1.

18.

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S.

Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.

19.

Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

Loree JM, Tan SK, Lafond LM, Speers CH, Kennecke HF, Cheung WY.

Clin Colorectal Cancer. 2018 Mar;17(1):65-72. doi: 10.1016/j.clcc.2017.10.011. Epub 2017 Oct 23.

PMID:
29153430
20.

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.

Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJM, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ.

Cold Spring Harb Mol Case Stud. 2018 Feb 1;4(1). pii: a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.

21.

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.

Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, Shaw KRM, Kopetz S.

Oncotarget. 2017 Jun 3;8(34):57882-57888. doi: 10.18632/oncotarget.18357. eCollection 2017 Aug 22.

22.

Recent developments in the treatment of metastatic colorectal cancer.

Loree JM, Kopetz S.

Ther Adv Med Oncol. 2017 Aug;9(8):551-564. doi: 10.1177/1758834017714997. Epub 2017 Jun 29. Review.

23.

Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.

Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM, Conrad C, Tzeng CD, Xiao L, Aloia TA, Eng C, Kopetz SE, Lichtarge O, Vauthey JN.

Ann Surg. 2019 May;269(5):917-923. doi: 10.1097/SLA.0000000000002450.

PMID:
28767562
24.

Platelet "first responders" in wound response, cancer, and metastasis.

Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV.

Cancer Metastasis Rev. 2017 Jun;36(2):199-213. doi: 10.1007/s10555-017-9682-0. Review.

25.

Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer.

Loree JM, Kopetz S.

J Natl Compr Canc Netw. 2017 Apr;15(4):545-547. No abstract available.

PMID:
28404763
26.

Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.

Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S.

Clin Cancer Res. 2017 Aug 15;23(16):4578-4591. doi: 10.1158/1078-0432.CCR-17-0232. Epub 2017 Apr 11.

27.

Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.

Loree JM, Kopetz S, Raghav KP.

J Gastrointest Oncol. 2017 Feb;8(1):199-212. doi: 10.21037/jgo.2017.01.01. Review.

28.

Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer.

Loree JM, Kennecke HF, Lee-Ying RM, Goodwin RA, Powell ED, Tang PA, Price Hiller JA, Vickers MM, Cheung WY.

Am J Clin Oncol. 2018 Jul;41(7):643-648. doi: 10.1097/COC.0000000000000342.

PMID:
27819876
29.

Impact of Travel Distance and Urban-Rural Status on the Multidisciplinary Management of Rectal Cancer.

Loree JM, Javaheri KR, Lefresne SV, Speers CH, Ruan JY, Chang JT, Brown CJ, Kennecke HF, Olson RA, Cheung WY.

J Rural Health. 2017 Sep;33(4):393-401. doi: 10.1111/jrh.12219. Epub 2016 Oct 7.

PMID:
27717002
30.

Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma.

Loree JM, Cai E, Sheffield BS, Dutz JP, Villa D, Shepherd LE, Connors JM, Sehn LH, Savage KJ.

Leuk Lymphoma. 2017 Mar;58(3):711-714. doi: 10.1080/10428194.2016.1204657. Epub 2016 Aug 25. No abstract available.

PMID:
27557805
31.

Optimizing adjuvant therapy and survivorship care of stage III colon cancer.

Loree JM, Cheung WY.

Future Oncol. 2016 Sep;12(17):2021-35. doi: 10.2217/fon-2016-0109. Epub 2016 Jun 15. Review.

PMID:
27301775
32.

Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy.

Loree JM, Kennecke HF, Renouf DJ, Lim HJ, Vickers MM, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2016 Dec;15(4):352-359.e1. doi: 10.1016/j.clcc.2016.04.003. Epub 2016 May 7.

PMID:
27265355
33.

Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases.

Loree JM, Hiruki T, Kennecke HF.

Case Rep Oncol. 2016 Jan 30;9(1):76-82. doi: 10.1159/000443985. eCollection 2016 Jan-Apr.

34.

CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL.

Clin Colorectal Cancer. 2014 Sep;13(3):172-7. doi: 10.1016/j.clcc.2014.01.001. Epub 2014 Feb 6.

PMID:
24630275
35.

Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL.

J Gastrointest Cancer. 2014 Jun;45(2):154-60. doi: 10.1007/s12029-013-9574-7.

PMID:
24408272

Supplemental Content

Loading ...
Support Center